Home Featured Page 228

Featured

Latest

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First...

Psychedelic Bulletin: Deconstructing COMPASS Pathways’ Phase 2b Results

Mindset Pharma Announces Poster Presentation of Preclinical Data for Benchmarking Next-Generation...

PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

Silo Pharma Reports Third Quarter Results and Operating Highlights

Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’...

Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials

Entheon Biomedical Announces Recruitment Underway in EBIQ-101 Clinical Study

Nova Mentis Files Genetic Neuroinflammatory Disease Patent

MYND Executes LOI to Enter into a Clinical Research Collaboration with...

EDITOR PICKS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Who Gets to Heal?

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First...

Psychedelic Bulletin: Deconstructing COMPASS Pathways’ Phase 2b Results

Mindset Pharma Announces Poster Presentation of Preclinical Data for Benchmarking Next-Generation...

PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

Silo Pharma Reports Third Quarter Results and Operating Highlights

Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’...

Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials

Entheon Biomedical Announces Recruitment Underway in EBIQ-101 Clinical Study

Nova Mentis Files Genetic Neuroinflammatory Disease Patent

MYND Executes LOI to Enter into a Clinical Research Collaboration with...

EDITOR PICKS

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY